1 Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands. Electronic address: r.ismail@dica.nl.
2 Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan, 1118, Amsterdam, 1081HZ, the Netherlands.
3 Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333ZA, the Netherlands.
4 Medicines Evaluation Board, Graadt van Roggenweg 500, Utrecht, 3531AH, the Netherlands.
5 Co€operatie VGZ U.A, Nieuwe Stationsstraat 12, Arnhem, 6811KS, the Netherlands.
6 Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713, GZ, the Netherlands.
7 University of Groningen, University Medical Center Groningen, University Center for Geriatric Medicine, Hanzeplein 1, Groningen, 9700, RB, the Netherlands.
8 Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands; Medicines Evaluation Board, Graadt van Roggenweg 500, Utrecht, 3531AH, the Netherlands.
9 Medicines Evaluation Board, Graadt van Roggenweg 500, Utrecht, 3531AH, the Netherlands; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, 9713, GZ, the Netherlands.
10 Department of Pharmacy, Rode Kruis Ziekenhuis, Vondellaan 13, Beverwijk, 1942LE, the Netherlands.